Published 9 hours ago • loading... • Updated 4 hours ago
Investigational Antibody-Drug Conjugate Shows Promise in Advanced Head and Neck Cancer
The antibody-drug conjugate also produced a 6.7-month median progression-free survival and an 81% estimated one-year survival in the phase I study.
Summary by News Medical
4 Articles
4 Articles
Investigational antibody-drug conjugate shows promise in advanced head and neck cancer
The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase 1 trial presented by researchers at The University of Texas MD Anderson Cancer Center.
Experimental ADC Shows Promising Initial Activity in Head and Neck Cancers
The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase 1 trial presented by researchers at The University of Texas MD Anderson Cancer Center.
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center2Last Updated100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium







